It is well established that glucagon-like peptide-1 (GLP-1), which is now routinely exploited in the clinical management of hyperglycaemia associated with type 2 diabetes (e.g. exenatide, saxagliptin), exerts important cardiovascular actions in both health and disease [1]. The gene discussed is GLP1R; the disease is Hyperglycemia.